Study Of The Ketogenic Agent AC 1202 In Mild To Moderate Alzheimer S Disease A Randomized, Double Blind, Placebo Controlled, Multicenter Trial

This study investigated whether AC-1202, a supplement that triggers the body to produce ketones (alternative brain fuel), could help people with Alzheimer's disease think more clearly. The brain typically runs on glucose (sugar), but in Alzheimer's disease, the brain struggles to use glucose effectively. Ketones can serve as backup fuel that the brain can still process efficiently.

Researchers tested AC-1202 in 152 people with mild to moderate Alzheimer's disease over 90 days. Participants continued their normal medications and diet while taking either the ketone supplement or a placebo. The study measured cognitive performance using standardized tests that assess memory, attention, and thinking skills.

The results showed that AC-1202 successfully raised ketone levels in the blood and led to meaningful improvements in cognitive test scores after 45 days of treatment. The benefits were most pronounced in people who don't carry the APOE4 gene variant, which is known to increase Alzheimer's risk. These participants showed sustained improvements that lasted through the full 90-day study period.

This research is significant for metabolic health because it demonstrates how alternative brain fuels might help when normal glucose metabolism is impaired. The findings suggest that ketogenic approaches could offer a nutritional strategy for supporting brain function in neurodegenerative conditions. In clinical practice, this type of metabolic intervention represents a complementary approach that could work alongside traditional Alzheimer's treatments, particularly for patients interested in addressing the metabolic aspects of brain health.